[
  {
    "ts": "2026-02-23T10:30:00+00:00",
    "headline": "3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds",
    "summary": "Viking stock has plenty of room to run.",
    "url": "https://www.fool.com/investing/2026/02/23/3-reasons-viking-therapeutics-stock-could-10x/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "9dabe636-10b2-3921-929f-f0971dee2050",
      "content": {
        "id": "9dabe636-10b2-3921-929f-f0971dee2050",
        "contentType": "STORY",
        "title": "3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds",
        "description": "",
        "summary": "Viking stock has plenty of room to run.",
        "pubDate": "2026-02-23T10:30:00Z",
        "displayTime": "2026-02-23T10:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/40166dc06a1cc3bf0520a3b3dc811c96",
          "originalWidth": 1400,
          "originalHeight": 923,
          "caption": "A researcher works at a laptop in a lab.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8ms0ndEUmtXrFkkoECWj0w--~B/aD05MjM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/40166dc06a1cc3bf0520a3b3dc811c96.cf.webp",
              "width": 1400,
              "height": 923,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6DyizSm4MwCeb5llJR76Lg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/40166dc06a1cc3bf0520a3b3dc811c96.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/23/3-reasons-viking-therapeutics-stock-could-10x/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-reasons-viking-therapeutics-stock-103000062.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T10:11:20+00:00",
    "headline": "Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial",
    "summary": "COPENHAGEN, Feb 23 () - Novo Nordisk said on Monday its next-generation obesity drug CagriSema ‚Äåwas less effective than Eli Lilly's tirzepatide ‚Äåin a head-to-head trial, a setback in the race ‚Äãfor dominance in the weight-loss drug market. The trial was designed to show CagriSema was at least as effective as tirzepatide in reducing weight, but ‚Äåfailed to meet ‚Å†that goal, Novo said in a statement.",
    "url": "https://uk.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "7eb5501f-7c94-3163-8c4e-8412730553d9",
      "content": {
        "id": "7eb5501f-7c94-3163-8c4e-8412730553d9",
        "contentType": "STORY",
        "title": "Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial",
        "description": "",
        "summary": "COPENHAGEN, Feb 23 () - Novo Nordisk said on Monday its next-generation obesity drug CagriSema ‚Äåwas less effective than Eli Lilly's tirzepatide ‚Äåin a head-to-head trial, a setback in the race ‚Äãfor dominance in the weight-loss drug market. The trial was designed to show CagriSema was at least as effective as tirzepatide in reducing weight, but ‚Äåfailed to meet ‚Å†that goal, Novo said in a statement.",
        "pubDate": "2026-02-23T10:11:20Z",
        "displayTime": "2026-02-23T10:11:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7",
          "originalWidth": 800,
          "originalHeight": 572,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oBGYgL02vdNB3H_4k.SyNw--~B/aD01NzI7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7.cf.webp",
              "width": 800,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yW1zE99MZUHRvddOxzpIIg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:36:50+00:00",
    "headline": "Novo Nordisk Weight-Loss Drug Less Effective Than Eli Lilly's, Trial Data Shows",
    "summary": "Novo Nordisk (NVO) US-listed shares fell early Monday after the latest trial results of the Danish p",
    "url": "https://finance.yahoo.com/news/novo-nordisk-weight-loss-drug-113650789.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "a7adad91-791a-3260-81a9-d2c8ff1fd755",
      "content": {
        "id": "a7adad91-791a-3260-81a9-d2c8ff1fd755",
        "contentType": "STORY",
        "title": "Novo Nordisk Weight-Loss Drug Less Effective Than Eli Lilly's, Trial Data Shows",
        "description": "",
        "summary": "Novo Nordisk (NVO) US-listed shares fell early Monday after the latest trial results of the Danish p",
        "pubDate": "2026-02-23T11:36:50Z",
        "displayTime": "2026-02-23T11:36:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/mt_newswires_premium_news_706/f360f3dd1acd0991db5012422fc00211",
          "originalWidth": 1000,
          "originalHeight": 666,
          "caption": "novonordisk - Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eliLOTQZlBN.EI2msY8t5Q--~B/aD02NjY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/mt_newswires_premium_news_706/f360f3dd1acd0991db5012422fc00211.cf.webp",
              "width": 1000,
              "height": 666,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Wm42B1.q1CBU9m2gxaHtkw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/mt_newswires_premium_news_706/f360f3dd1acd0991db5012422fc00211.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-weight-loss-drug-113650789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-weight-loss-drug-113650789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:36:37+00:00",
    "headline": "Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Monday; Novo Nordisk, Strategy to Decline",
    "summary": "The most-talked-about stocks in the Reddit subforum Wallstreetbets were mostly lower hours before Mo",
    "url": "https://finance.yahoo.com/news/social-buzz-wallstreetbets-stocks-mostly-113637624.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "9fedea89-ba6c-3d18-bdc6-5b18e61d4744",
      "content": {
        "id": "9fedea89-ba6c-3d18-bdc6-5b18e61d4744",
        "contentType": "STORY",
        "title": "Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Monday; Novo Nordisk, Strategy to Decline",
        "description": "",
        "summary": "The most-talked-about stocks in the Reddit subforum Wallstreetbets were mostly lower hours before Mo",
        "pubDate": "2026-02-23T11:36:37Z",
        "displayTime": "2026-02-23T11:36:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/social-buzz-wallstreetbets-stocks-mostly-113637624.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/social-buzz-wallstreetbets-stocks-mostly-113637624.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "AM"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MSTR"
            },
            {
              "symbol": "HOOD"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "MSFT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:07:00+00:00",
    "headline": "Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Rival in Trial",
    "summary": "Shares fell sharply after the Danish drugmaker said its CagriSema experimental obesity drug failed to beat the weight loss delivered by Eli Lilly‚Äôs Zepbound in a head-to-head clinical trial.",
    "url": "https://www.wsj.com/health/pharma/novo-nordisk-shares-slide-after-obesity-drug-misses-key-goal-in-trial-263845ba?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "882d8a85-7d67-34a5-9359-3e21c423286a",
      "content": {
        "id": "882d8a85-7d67-34a5-9359-3e21c423286a",
        "contentType": "STORY",
        "title": "Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Rival in Trial",
        "description": "",
        "summary": "Shares fell sharply after the Danish drugmaker said its CagriSema experimental obesity drug failed to beat the weight loss delivered by Eli Lilly‚Äôs Zepbound in a head-to-head clinical trial.",
        "pubDate": "2026-02-23T11:07:00Z",
        "displayTime": "2026-02-23T11:07:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/882d8a85-7d67-34a5-9359-3e21c423286a/novo-nordisk-shares-plunge.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/1299d3fc5e2b731f491be8edaf27536d",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MyL48X4s4gpQWSdt3IrYQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/1299d3fc5e2b731f491be8edaf27536d.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmXDncVkC6u9q6z0TItpZg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/1299d3fc5e2b731f491be8edaf27536d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/novo-nordisk-shares-slide-after-obesity-drug-misses-key-goal-in-trial-263845ba?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T10:58:00+00:00",
    "headline": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Eli Lilly, Paramount, Nvidia, and More",
    "summary": "Nvidia shares tick up as investors await the chip maker‚Äôs fourth-quarter earnings, which likely will reveal how artificial-intelligence demand is holding up.",
    "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
      "content": {
        "id": "f7d77d0b-860e-34ff-a495-c3fdff8b2514",
        "contentType": "STORY",
        "title": "These Stocks Are Today‚Äôs Movers: Novo Nordisk, Eli Lilly, Paramount, Nvidia, and More",
        "description": "",
        "summary": "Nvidia shares tick up as investors await the chip maker‚Äôs fourth-quarter earnings, which likely will reveal how artificial-intelligence demand is holding up.",
        "pubDate": "2026-02-23T10:58:00Z",
        "displayTime": "2026-02-23T10:58:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f7d77d0b-860e-34ff-a495-c3fdff8b2514/these-stocks-are-today%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YpTBpBgno7NJFmEn4fooOg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SCGkZGeqjG9WPS36b0yD8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/df08f3da8dd8358a03fd841d483851f3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-8d657e53?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PSKY"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NVDA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T10:56:49+00:00",
    "headline": "Podcast: Which pharma and medtech companies came out on top in 2025 revenues?",
    "summary": "The healthcare editorial teams discusses the key trends and growth drivers in companies' recent 2025 financial results.",
    "url": "https://www.pharmaceutical-technology.com/features/podcast-which-pharma-and-medtech-companies-came-out-on-top-in-2025-revenues/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "4c21b03b-ac35-3ab5-9dac-67690432c5c0",
      "content": {
        "id": "4c21b03b-ac35-3ab5-9dac-67690432c5c0",
        "contentType": "STORY",
        "title": "Podcast: Which pharma and medtech companies came out on top in 2025 revenues?",
        "description": "",
        "summary": "The healthcare editorial teams discusses the key trends and growth drivers in companies' recent 2025 financial results.",
        "pubDate": "2026-02-23T10:56:49Z",
        "displayTime": "2026-02-23T10:56:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/cecf72fe419727e27c4297cfdfb8724e",
          "originalWidth": 1000,
          "originalHeight": 377,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QpPJwBSei73InI9Ki9UVfg--~B/aD0zNzc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/cecf72fe419727e27c4297cfdfb8724e.cf.webp",
              "width": 1000,
              "height": 377,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/34PHKYhhEBdL8cBWzz97_w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/cecf72fe419727e27c4297cfdfb8724e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/features/podcast-which-pharma-and-medtech-companies-came-out-on-top-in-2025-revenues/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/podcast-pharma-medtech-companies-came-105649000.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "EW"
            },
            {
              "symbol": "MDT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T10:06:24+00:00",
    "headline": "Stocks to Watch Monday: Domino's Pizza, Novo Nordisk, Eli Lilly, Delta",
    "summary": "üîé American Airlines (AAL), Delta Air Lines (DAL) and United Airlines (UAL): A blizzard caused mass flight cancellations on the East Coast. More than 8,000 flights scheduled for Sunday and Monday had been canceled as of Sunday afternoon, according to FlightAware.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
      "content": {
        "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Domino's Pizza, Novo Nordisk, Eli Lilly, Delta",
        "description": "",
        "summary": "üîé American Airlines (AAL), Delta Air Lines (DAL) and United Airlines (UAL): A blizzard caused mass flight cancellations on the East Coast. More than 8,000 flights scheduled for Sunday and Monday had been canceled as of Sunday afternoon, according to FlightAware.",
        "pubDate": "2026-02-23T10:06:24Z",
        "displayTime": "2026-02-23T10:06:24Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cb781f9d-b9a5-3f5a-bfb4-b439b3b47382/stocks-to-watch-monday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KnlNOKh2C6QgkEmemrj6mg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zhLP7itajp.wiPUq1vzKdA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO.B"
            },
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "DAL"
            },
            {
              "symbol": "FBIN"
            },
            {
              "symbol": "AAL"
            },
            {
              "symbol": "UAL"
            },
            {
              "symbol": "D"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:59:38+00:00",
    "headline": "Novo Nordisk Dives As Next-Gen Obesity Drug Fails To Match Eli Lilly's Zepbound",
    "summary": "Novo Nordisk stock dived after Novo's next-generation obesity drug CagriSema didn't match weight loss from Eli Lilly's Zepbound. Lilly stock rose.",
    "url": "https://www.investors.com/news/technology/novo-nordisk-dives-next-gen-obesity-drug-fails-to-match-eli-lilly-zepbound/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "768f33a0-eb6d-3261-823c-4bb7c71825e8",
      "content": {
        "id": "768f33a0-eb6d-3261-823c-4bb7c71825e8",
        "contentType": "STORY",
        "title": "Novo Nordisk Dives As Next-Gen Obesity Drug Fails To Match Eli Lilly's Zepbound",
        "description": "",
        "summary": "Novo Nordisk stock dived after Novo's next-generation obesity drug CagriSema didn't match weight loss from Eli Lilly's Zepbound. Lilly stock rose.",
        "pubDate": "2026-02-23T12:59:38Z",
        "displayTime": "2026-02-23T12:59:38Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/768f33a0-eb6d-3261-823c-4bb7c71825e8/novo-nordisk-dives-as.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/5dcb64c0eaa4cddb85491e2fdb5e1d5f",
          "originalWidth": 1000,
          "originalHeight": 511,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ROtisKKZCPH047T1qbT2JQ--~B/aD01MTE7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/5dcb64c0eaa4cddb85491e2fdb5e1d5f.cf.webp",
              "width": 1000,
              "height": 511,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kZHoeLqHyXHi9aWRxqpbIw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/5dcb64c0eaa4cddb85491e2fdb5e1d5f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/novo-nordisk-dives-next-gen-obesity-drug-fails-to-match-eli-lilly-zepbound/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "GPCR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:39:06+00:00",
    "headline": "Novo Nordisk flags board members for re-election amid restructuring efforts",
    "summary": "Three new board and shareholder-elected members could join Novo‚Äôs council, which largely consists of recent appointees following a restructure in October 2025.",
    "url": "https://www.pharmaceutical-technology.com/news/novo-nordisk-board-shakeup-election-recommendations/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "2574fae0-1781-3486-bc4a-4e85119277e7",
      "content": {
        "id": "2574fae0-1781-3486-bc4a-4e85119277e7",
        "contentType": "STORY",
        "title": "Novo Nordisk flags board members for re-election amid restructuring efforts",
        "description": "",
        "summary": "Three new board and shareholder-elected members could join Novo‚Äôs council, which largely consists of recent appointees following a restructure in October 2025.",
        "pubDate": "2026-02-23T12:39:06Z",
        "displayTime": "2026-02-23T12:39:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/65120f4c2796e98f05dc97d112e4b3d6",
          "originalWidth": 1000,
          "originalHeight": 666,
          "caption": "Shareholders will determine the composition of Novo Nordisk's board in an Annual General Meeting on the 26 March. Credit: Below the Sky/Shutterstock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ySMzM4tODIOV7y_P0R3O7Q--~B/aD02NjY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/65120f4c2796e98f05dc97d112e4b3d6.cf.webp",
              "width": 1000,
              "height": 666,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DMI7l1Dr.8PjmJkLBHD2YQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/65120f4c2796e98f05dc97d112e4b3d6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/novo-nordisk-board-shakeup-election-recommendations/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-flags-board-members-123906245.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "GMAB"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "TAK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:38:00+00:00",
    "headline": "1 Reason I'm Seriously Considering Novo Nordisk as a Buy‚Äëand‚ÄëNever‚ÄëSell Obesity Stock",
    "summary": "Novo Nordisk investors get a second bite at the Ozempic apple.",
    "url": "https://www.fool.com/investing/2026/02/23/1-reason-im-seriously-considering-novo-nordisk/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "22c9983e-1e59-377d-86dc-119adf0e52eb",
      "content": {
        "id": "22c9983e-1e59-377d-86dc-119adf0e52eb",
        "contentType": "STORY",
        "title": "1 Reason I'm Seriously Considering Novo Nordisk as a Buy‚Äëand‚ÄëNever‚ÄëSell Obesity Stock",
        "description": "",
        "summary": "Novo Nordisk investors get a second bite at the Ozempic apple.",
        "pubDate": "2026-02-23T12:38:00Z",
        "displayTime": "2026-02-23T12:38:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/ffc38f11cb377c1103f672ac1cce2bbc",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "A person using a GLP-1 injector pen.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vkqbtsuiusy6b2MrKdaKlw--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/ffc38f11cb377c1103f672ac1cce2bbc.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kBRRw6b9b3ZaNUMosBwTXw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/ffc38f11cb377c1103f672ac1cce2bbc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/23/1-reason-im-seriously-considering-novo-nordisk/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-reason-im-seriously-considering-123800435.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:35:16+00:00",
    "headline": "Stocks Down Pre-Bell as Trump Raises Global Tariffs Following Supreme Court Ruling",
    "summary": "The benchmark US stock measures were tracking in the red before the opening bell Monday as President",
    "url": "https://finance.yahoo.com/news/stocks-down-pre-bell-trump-123516237.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "c72c4c07-0aa8-3182-af08-26f22d926db5",
      "content": {
        "id": "c72c4c07-0aa8-3182-af08-26f22d926db5",
        "contentType": "STORY",
        "title": "Stocks Down Pre-Bell as Trump Raises Global Tariffs Following Supreme Court Ruling",
        "description": "",
        "summary": "The benchmark US stock measures were tracking in the red before the opening bell Monday as President",
        "pubDate": "2026-02-23T12:35:16Z",
        "displayTime": "2026-02-23T12:35:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/mt_newswires_premium_news_706/8685121785649cec3dbcdbbd25333a86",
          "originalWidth": 1024,
          "originalHeight": 683,
          "caption": "wall street stock market flag new york trading equity - Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QVMgErJdOR7IkzCjRHm3pQ--~B/aD02ODM7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/mt_newswires_premium_news_706/8685121785649cec3dbcdbbd25333a86.cf.webp",
              "width": 1024,
              "height": 683,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dimQxOClk1isv1IKNf9JtA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/mt_newswires_premium_news_706/8685121785649cec3dbcdbbd25333a86.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/stocks-down-pre-bell-trump-123516237.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stocks-down-pre-bell-trump-123516237.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^DJI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:41:55+00:00",
    "headline": "Novo Nordisk's CagriSema trial deals a blow in obesity drug rivalry with Eli Lilly",
    "summary": "COPENHAGEN, Feb 23 () - Novo Nordisk's next-generation obesity drug CagriSema was less effective than Eli Lilly's tirzepatide in a head-to-head trial, the Danish drugmaker said on Monday, in a setback to its ‚Äåefforts to dominate the weight-loss market. Novo Nordisk is fighting to regain first-mover advantage in the obesity ‚Äåtreatment market, where demand for drugs with higher efficacy has surged.",
    "url": "https://uk.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "7eb5501f-7c94-3163-8c4e-8412730553d9",
      "content": {
        "id": "7eb5501f-7c94-3163-8c4e-8412730553d9",
        "contentType": "STORY",
        "title": "Novo Nordisk's CagriSema trial deals a blow in obesity drug rivalry with Eli Lilly",
        "description": "",
        "summary": "COPENHAGEN, Feb 23 () - Novo Nordisk's next-generation obesity drug CagriSema was less effective than Eli Lilly's tirzepatide in a head-to-head trial, the Danish drugmaker said on Monday, in a setback to its ‚Äåefforts to dominate the weight-loss market. Novo Nordisk is fighting to regain first-mover advantage in the obesity ‚Äåtreatment market, where demand for drugs with higher efficacy has surged.",
        "pubDate": "2026-02-23T11:41:55Z",
        "displayTime": "2026-02-23T11:41:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7",
          "originalWidth": 800,
          "originalHeight": 572,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oBGYgL02vdNB3H_4k.SyNw--~B/aD01NzI7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7.cf.webp",
              "width": 800,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yW1zE99MZUHRvddOxzpIIg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/235aa21d1918c06918a6104f6e73b3e7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-obesity-drug-cagrisema-100546806.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:32:02+00:00",
    "headline": "Stocks to Watch Monday: Domino's Pizza, Eli Lilly, Merck, Gilead",
    "summary": "‚ÜóÔ∏è Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. Shares rose roughly 1.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
      "content": {
        "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Domino's Pizza, Eli Lilly, Merck, Gilead",
        "description": "",
        "summary": "‚ÜóÔ∏è Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. Shares rose roughly 1.",
        "pubDate": "2026-02-23T11:32:02Z",
        "displayTime": "2026-02-23T11:32:02Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cb781f9d-b9a5-3f5a-bfb4-b439b3b47382/stocks-to-watch-monday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KnlNOKh2C6QgkEmemrj6mg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zhLP7itajp.wiPUq1vzKdA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NOVO.B"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "AAL"
            },
            {
              "symbol": "DAL"
            },
            {
              "symbol": "UAL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]